|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
|
Given how vital the practice is to international regulatory compliance and to keeping products safely on the market, it may be expected that global life sciences firms would have the production and management of patient-facing materials efficiently coordinated so that accuracy and speed to market were taken for granted. Nothing could be further from reality.
Undoubtedly, the global labelling management burden in life sciences has soared in recent years. Companies’ R&D ambitions are growing, businesses are expanding into more markets, and regulators are steadily strengthening safety requirements to protect patients from harm. Each time the benefit/risk profile or safety factors change, or as regional or local regulatory agencies update their standards, international biopharmaceutical firms must react swiftly with accurate, compliant labelling for all affected markets. If they fail to do so, they risk delays to shipping or even to keeping their product registrations on the market, with implications for sales, revenues, and reputation.
Given that all of these market conditions are set to intensify rather than diminish, finding a solution sooner is now a priority. Balancing market opportunity, risk, and cost is becoming increasingly tough to do, so it is unsurprising that organisations are keen to bring the situation under control. As the frequency of changes increases − due to ever-growing product complexity, heightened pharmacovigilance, and new regulatory specifications – the demand soars exponentially.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Turkish Cargo maintains its steady growth.
According to the data obtained by WACD, the international air cargo
information provider, in May; Turkish Cargo, the global air cargo brand
providing service to 124 countries around the world, increased its
tonnage rate by 7.1 percent, and grew substantially across the industry
which shrank by 5.1 percent in the global air cargo market.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Emerging Markets: Goldmines or Landmines?
Pharm-Olam, LLC
Over the past decade, biopharmaceutical companies
have increasingly turned to emerging markets as a way
to reduce clinical trial costs and timelines. Areas such
as Eastern Europe, India, and Latin America—with their
ready population of treatment naïve patients—can be an
answer to the intense competition for patients seen in
developed markets. Many of the countries within these
regions may now be considered as “emerged” countries
but yet, conducting trials in these regions does require
some special attention and expertise. Before deciding to
conduct studies in these areas, companies should have a
full appreciation for the ethical, medical, regulatory, legal,
and operational hurdles that must be surmounted for
success. Here we highlight a number of those issues and
offer our recommendations for how sponsor companies
can deal with them effectively.
More info >> |
|
 |
Industry Events |
 |
Pharmapack Europe 2020
5-6 February 2020, Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
More info >> |
|
|
